Pharmaceuticals, Biotechnology and Life Sciences
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis
Alvotech has enrolled the first patient to test its Humira biosimilar candidate in Alvopad PS, in a Phase III clinical study (ALVOPAD PS), for adult patients with moderate to severe chronic plaque psoriasis.
Novartises division Sandoz has asked the FDA to review their Biologic License Application for biosimilar adalimumad, related to Humira, for…
The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since becoming an independent company in 2013.
Amgen has filed a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501,…